Extract

Dear Editor, We thank Weizhen Tang et al. for their interest in our study on HCQ blood concentrations in pregnant patients with SLE and their association with maternal and foetal outcomes [1]. However, we would like to clarify several points that appear to have been misunderstood or overlooked.

First and foremost, as explicitly stated in our paper, we refrained from performing multivariate analyses due to the limited number of events (notably only four severe flares in the total cohort). Consequently, our results are presented solely as univariate analyses, making adjustments impossible.

More specifically, regarding the comment on other autoimmune diseases, the indication for HCQ was exclusively for SLE in all our patients. None had primary SS (but seven had a secondary SS) and two had RA, but HCQ is not recommended for RA treatment [2, 3] and therefore it is highly unlikely that HCQ would be prescribed for RA in our cohort. Therefore, its effect on the overall results is likely negligible.

You do not currently have access to this article.

Comments

0 Comments
Submit a comment
You have entered an invalid code
Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.